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MicroRNAs and their role in aggressive cancers
The past decade has shown remarkable advances in our 
knowledge of microRNAs (miRNAs) and their functional 
importance in a wide range of developmental and physio­
logical  processes.  These  small  endogenous  non­coding 
RNAs, which post­transcriptionally regulate the expres­
sion of several hundred genes, have recently been shown 
to have an important role in various human cancers [1]. 
There is growing evidence that miRNAs are critical in 
cancer  predisposition,  initiation  and  progression,  with 
several miRNAs demonstrating oncogenic and/or tumor 
suppressor properties. In the past decade, several studies 
have  focused  on  exploring  the  connection  of  miRNAs 
with tumor proliferation, invasion, migration and stem­
cell behavior. Because of the widespread dysregulation of 
miRNAs in all types of tumors, their expression profiles 
are useful diagnostic and prognostic signature classifiers. 
miRNA expression analysis has confirmed that specific 
miRNAs  show  differential  expression  patterns  among 
normal and tumor tissues. For example, the miRNA miR­
10b is specifically overexpressed only in metastatic breast 
cancers but downregulated in primary breast tumors [2], 
and  miR­335  and  miR­126  are  lost  in  relapsed  breast 
cancers with distal metastasis [3]. miRNAs are also found 
to be specifically overexpressed in resistant tumors with 
poor prognosis. Thus, specific miRNAs are involved in 
different phenotypes of aggressive cancers, providing an 
important rationale for their investigation as therapeutic 
targets.
New insights into the role of miR-221 and miR-222 
as regulators in basal-like breast cancer
A recent study published in Science Signaling by Stinson 
et al. [4] identified miR­221 and miR­222 as regulators of 
epithelial­to­mesenchymal transition (EMT) using high­
throughput  analysis  and  a  human  in  vitro  cell  culture 
model.  The  study  [4]  reported  miR­221/222  to  be 
specifically expressed in basal­like breast cancer and to 
act downstream of the oncogenic RAS­RAF­MEK path­
way. These miRNAs mediate metastasis through increased 
invasion and migration by targeted repression of tricho­
rhino­phalangeal  syndrome  type  1  protein  (TRPS1), 
which  in  turn  increases  the  abundance  of  the  EMT­
promoting protein zinc finger E­box­binding homeobox 2 
(ZEB2). Stinson et al. [4] further explore the involve  ment 
of miRNAs in promotion of clinically aggressive meta­
static breast cancer (Figure 1).
The study by Stinson and colleagues [4] is significant 
because it substantiates the concept that specific miRNAs 
can promote transformation to more aggressive cancer 
phenotypes with poor prognosis. The authors performed 
miRNA  microarray  screening  using  multiple  cell  lines 
representing  luminal­like  and  basal­like  subtypes  of 
breast cancer, and identified miR­221/222 to be differen­
tially expressed. The overexpression of miR­221/222 in 
estrogen receptor (ER)­negative breast cancer has been 
reported previously [5], implying a role of miR­221/222 
in  predisposition  of  ER  status  in  aggressive  breast 
cancers. Transfection of miR­221/222 synthetic mimetics 
into an immortalized and nontransformed mammary cell 
line  (MCF10A)  resulted  in  a  significant  enrichment  of 
genes  involved  in  EMT  and  the  RAS  pathway. 
miR­221/222  induced  EMT­like  characteristics,  with 
enhanced invasion and migration, increased levels of the 
mesenchymal marker vimentin and reduced levels of the 
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© 2011 BioMed Central Ltdepithelial marker E­cadherin. Consequently, treatment of 
MDA­MB­231 cells (a metastatic basal­like breast cancer 
cell line) with miR­221/222 inhibitors induced a reverse 
phenotype  with  mesenchymal­to­epithelial  transition 
(MET)­like characteristics [4]. The reversal to MET by 
inhibiting miR­221/222 is an important finding that can 
be therapeutically exploited, but more in vivo studies will 
be required before any significance can be established.
In addition, the authors [4] confirmed the correlation 
between increased miR­221/222 levels and vimentin and 
E­cadherin expression in primary breast cancer samples. 
Previous reports [6] have established that miR­200 family 
members (miR­200a, miR­200b, miR­200c, miR­141 and 
miR­429) are downregulated in aggressive breast cancers. 
Thus,  a  combination  of  a  miR­221/222  and  miR­200 
signa  ture with other EMT markers such as vimentin and 
E­cadherin  can  provide  a  clinical  predictive  model  for 
identifying patients with poor prognosis.
The  authors  [4]  further  studied  the  regulation  of 
miR­221/222 and reported a novel association between 
miRNA and the EMT­promoting RAS­RAF­MEK signal­
ing pathway. They identified an upstream binding site for 
FOSL1,  a  member  of  the  FOS  family  of  transcription 
factors and, using chromatin immunoprecipitation and 
luciferase assays, they showed that the transcription of 
miR­221/222  is  regulated  by  FOSL1.  They  identified 
miR­221/222  as  downstream  of  the  epidermal  growth 
factor  receptor  (EGFR)­RAS­RAF­MEK  pathway  by 
show  ing that treatment with EGFR and MEK inhibitors 
knocked down the expression of both the miRNAs and 
FOSL1.  TRPS1,  a  transcription  factor  with  decreased 
abun  dance  in  clinically  aggressive  breast  cancers,  was 
identified  as  the  direct  target  of  miR­221/222;  and  in 
turn, TRPS1 targeted the EMT­suppressor protein ZEB2. 
Thus,  repression  of  TRPS1  by  miR­221/222  caused  an 
increase in the levels of ZEB2, which directly inhibits E­
cadherin  and  upregulates  vimentin,  promoting  EMT. 
These  results  together  reveal  an  intricate  association 
between  miR­221/222  and  the  EGFR­RAS­RAF­MEK 
cascade (Figure 1).
In  addition,  the  paper  [4]  highlights  the  functional 
significance of miRNAs in the process of EMT and stem­
cell formation in breast cancer [7]. The role of miR­335, 
miR­206 and miR­126 in suppressing breast cancer meta­
stasis was initially described by Tavazoie et al. [3], who 
reported that selective loss of miRNA expression induced 
metastatic  potential.  Other  studies  reported  increased 
expression of miR­10b, miR­21, miR­9 and miR­29b in 
malignant breast cancers [8], whereas the miR­200 family 
is downregulated in metastatic cancers [6]. These miRNAs 
function at different stages of the multistep metastatic 
cascade,  by  acting  as  direct  downstream  effectors  of 
oncogenes,  sensitizing  tumor  cells  to  signals  from  the 
tumor  microenvironment,  or  altering  expression  of 
EMT­related markers, such as E­cadherin and vimentin 
[7,8]. The study by Stinson et al. [4] elucidates a further 
layer of regulation that controls the EMT­driven cellular 
phenotype.
The study provides a logical association between the 
earlier studies demonstrating the importance of miR­221/ 
222 in metastatic breast cancers and drug resistance. An 
initial study by Zhao et al. [5] showed that miR­221/222 
directly  targeted  ERα  and  that  their  overexpression  in 
breast  cancer  contributed  to  progression  of  the  more 
aggressive  ER­negative  basal  phenotype  in  a  subset  of 
breast cancers. miR­221/222 have also been shown to act 
as oncogenes by repressing cell cycle inhibitor proteins 
p27/Kip1 and p57 and thus facilitating cell proliferation 
and  self­renewal  [9].  These  functions  of  miR­221/222 
both  contribute  to  tamoxifen  resistance  in  basal­type 
Figure 1. Involvement of miR-221/222 as downstream effectors 
of the EGFR-RAS-RAF-MEK pathway in progression of metastatic 
transformation of breast cancer tumors. EGFR, epidermal growth 
factor receptor; EMT, epithelial-to-mesenchymal transition; ER, 
estrogen receptor; ERK, extracellular signal-regulated kinase; FOSL1, 
FOS-like antigen 1; GRB2, growth factor receptor-bound protein 2; 
MEK, mitogen-activated protein/extracellular signal-regulated kinase 
kinase; p27Kip1, cyclin-dependent kinase inhibitor p27Kip1; SOS, Son of 
sevenless homolog; TRPS1, tricho-rhino-phalangeal syndrome type 1; 
ZEB, zinc finger E-box-binding homeobox.
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aspect to the story and links the basal­subtype­specific 
expression of miR­221/222 with increased abundance of 
mesenchymal markers and an enhanced EMT phenotype. 
It positions miR­221/222 downstream of the RAS path­
way, targeting TRPS1 and thus increasing the abundance 
of EMT­promoter ZEB2; this provides a clearer picture of 
the mechanism of miR­221/222 in promoting aggressive 
breast cancer phenotypes with chemoresistance and poor 
prognosis.
Finally,  another  important  finding  [4]  is  the  involve­
ment  of  different  miRNAs  in  different  phenotypes  of 
breast cancer. Previous studies have demonstrated that 
miR­200  family  miRNAs  act  as  EMT  repressors  by 
inhibiting  ZEB1  protein;  their  expression  levels  are 
greatly  reduced  in  metastatic  breast  cancers  compared 
with  normal  tissues  [6],  and  a  negative  feedback  loop 
connects  miR­200  family  expression,  ZEB1  expression 
and  EMT  occurrence  [10].  Stinson  et  al.  [4]  discuss 
possible involvement of the miR­221/222 family in this 
feedback  inhibition  of  miR­200  family  members:  they 
may act by relieving the TRPS1­mediated repression of 
ZEB2  protein  and  committing  cells  to  EMT.  Thus, 
regulation  of  the  miR­200  and  miR­221/222  families 
reflects a fine balance linking miRNAs as stimulators and 
inhibitors  of  metastasis  and  identifies  important 
molecular targets that could potentially control a specific 
tumor behavior.
The challenges ahead
In  conclusion,  these  new  findings  [4]  add  yet  another 
significant  dimension  to  the  regulation  of  the  EMT 
phenomenon. The report presents a critical link between 
the EMT­related miRNAs miR­221 and miR­222 and the 
process  of  EMT  and  metastasis  in  aggressive  breast 
cancers. The importance of Stinson et al.’s paper [4] rests 
in the identification of clinically useful miRNAs that act 
as  regulators  of  EMT  and  represent  not  only  a  novel 
therapeutic strategy for the treatment of advanced breast 
cancer, but also potential use as biomarkers for clinically 
aggressive  breast  cancers  with  poor  prognosis.  Direct 
functional screens of global miRNA expression profiles in 
transformed  tumor  cells  might  help  illuminate 
involvement of other miRNAs in EMT. Furthermore, the 
in  vivo  phenotypic  consequences  of  miR­221/222  gain 
and loss of function in mouse models will help evaluate 
the practicality of miR­221/222 expression manipulation 
for therapy of human breast cancers. Identification of the 
as yet unknown targets for miR­221/222 also remains a 
key  objective  for  the  design  of  novel­miRNA­based 
therapy.  Overexpressed  miRNAs  can  be  effectively 
inhibited  in  vivo  using  antisense  oligonucleotides  with 
specific  modifications,  such  as  cholesterol­conjugated 
antagomiRs,  locked  nucleic  acid  oligonucleotides  or 
2’­O­methyl modifications. However, several challenges 
regarding  the  stability  and  delivery  strategies  of  these 
anti­miRs still need to be answered before they can be 
useful as therapeutic agents. More experimental evidence 
establishing that correction of a specific miRNA altera­
tion can re­establish homeostasis and stabilize tumori­
genesis is required. In this regard, the potential conse­
quences of inducing MET in normal tissues during the 
course  of  miR­221/222  therapy  also  need  to  be  deter­
mined. Thus, miRNAs hold great potential as therapeutic 
targets  for  new  drug  development;  however,  more 
insights into the functional consequences and efficiency 
of  miRNA  inhibition  for  patient  survival  need  to  be 
addressed.
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